|
|
Our People
 Dr. David Ecker, Divisional Vice President, Ibis Site General Manager
Dave is a co-founder of Isis Pharmaceuticals and the founder of Ibis Biosciences, now a subsidiary of Abbott Molecular, Inc. Along with his core team, he was a primary inventor of the Ibis technology and Ibis T5000 technology. The technology was developed for infection control, and biological weapons defense sponsored by DARPA, CDC, NIAID, FBI, DHS and other U.S. government agencies. Currently responsible for the Ibis site and its employees in Carlsbad, California, Dave oversees the science, patents, business development, strategic direction and management of corporate and government partnerships. Dave has more than 26 years of experience in the pharmaceutical and biotechnology industry, in drug discovery and diagnostic platform technology development.
 Dr. Steven Hofstadler, Divisional Vice President, Ibis Research and Development
Steve received a Ph.D. in Chemistry from The University of Texas Department of Chemistry, where his work focused on the fundamentals and applications of electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Upon completing his graduate studies, he worked for about five years as a Post-Doctoral Research Fellow and subsequently Senior Research Scientist at Pacific Northwest National Laboratory in Richland, Washington. In 1997, he relocated to the Ibis division of Isis Pharmaceuticals, Inc. There his work centered on the mass spectrometric characterization of noncovalent complexes between RNA and small drug-like molecules. His current research interests focus on applications of high performance mass spectrometry for the analysis of nucleic acids as a means to characterize microorganisms and forensically differentiate humans. Steve is the author/co-author of more than 100 peer-reviewed publications and book chapters and holds more than 20 patents.
Urs G. Wiederkehr, General Manager, Commercial Laboratory Operation
Urs began managing this new, strategic business initiative for Abbott Laboratories in early 2009. Previously, as head of commercial operation, he successfully accelerated Abbott Molecular’s North American business. During 24 years in senior management positions at leading diagnostics companies such as Abbott and Ventana Medical Systems (now Roche), he gained extensive experience in strategic marketing, business development and commercial operations. Prior to rejoining Abbott, Urs was CEO of Cytolution, a start-up company developing a novel biomarker/flow cytometry-based device for cervical cancer screening. At Ventana, he was responsible for company strategy as Vice President of strategic marketing, and for commercial operations as VP and GM for North America. Urs previously held various GM and management positions at Abbott’s worldwide and European headquarters, as well as in several country organizations. At BioVeris/IGEN (now Roche), he was responsible for business development.
Dr. Kristin S. Lowery, Director, AthoGen Laboratory Operations
Kristin received a Ph.D. in Physical Chemistry from Stanford University. Upon completing her graduate studies, she was a Post-Doctoral Fellow in the Molecular Physics Laboratory at SRI International. She helped develop matrix-assisted laser desorption/ionization time-of flight mass spectrometry for DNA sequencing applications. Thereafter, she became a Post-Doctoral fellow in the Analytical Research group at Parke-Davis, where she helped develop electrospray ionization mass spectrometry methodologies for studying drug interactions with proteins and RNA. In 1998, Kristin joined Ibis Biosciences. She is presently the Laboratory Director of the Ibis Analytical Services Laboratory. Kristin is the author/co-author of 30-plus peer-reviewed publications and book chapters. Her most recent research interests include developing mass spectrometry methodologies for the analysis of nucleic acids as a means to characterize microorganisms and forensically differentiate humans.
|
|
|
